Prothena (NASDAQ:PRTA) Reaches New 12-Month Low at $20.32

Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $20.32 and last traded at $20.46, with a volume of 24302 shares. The stock had previously closed at $20.56.

Analysts Set New Price Targets

PRTA has been the topic of several recent research reports. Bank of America restated a "neutral" rating and set a $38.00 price target (down previously from $68.00) on shares of Prothena in a report on Tuesday, January 30th. Oppenheimer dropped their price objective on Prothena from $98.00 to $80.00 and set an "outperform" rating for the company in a report on Tuesday, February 20th. JMP Securities upped their price objective on Prothena from $81.00 to $85.00 and gave the company a "market outperform" rating in a research report on Friday, February 16th. Royal Bank of Canada decreased their target price on Prothena from $36.00 to $35.00 and set a "sector perform" rating for the company in a research report on Friday, February 16th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Prothena presently has a consensus rating of "Moderate Buy" and an average target price of $69.63.

Prothena Stock Performance

The firm's 50-day moving average price is $25.66 and its two-hundred day moving average price is $32.30. The stock has a market cap of $1.10 billion, a PE ratio of -7.34 and a beta of 0.21.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.03). The company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. The firm's quarterly revenue was down 99.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS. On average, analysts anticipate that Prothena Co. plc will post -4.88 earnings per share for the current year.

Institutional Trading of Prothena

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its position in Prothena by 265.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,122 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Prothena by 99.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,375 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 684 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Prothena in the 3rd quarter worth $74,000. Allspring Global Investments Holdings LLC grew its stake in Prothena by 58.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,096 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,140 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Prothena during the 4th quarter valued at about $222,000. 97.08% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.